Hyperphosphatemia

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

The FDA has approved Xphozah to reduce serum phosphorus in adults with chronic kidney disease on dialysis as an add-on therapy in patients who have an inadequate response to phosphate binders, according to a press release from Ardelyx Inc.

Ardelyx Inc. has been granted an appeal to a complete response letter issued last year by the FDA regarding the company’s new drug application for its phosphate absorption inhibitor drug Xphozah.

Phosphate binders are not the only way to lower phosphorous levels in patients on dialysis with hyperphosphatemia, according to a speaker at the virtual Annual Dialysis Conference.

Low-dose sevelamer in combination with a calcium-based phosphorus binder may be used in resource-constrained countries as a second-line therapy for patients with hyperphosphatemia to minimize calcium loading.

Data from a single-center, cross-sectional study showed medications commonly prescribed to patients with chronic kidney disease were low in inorganic phosphorus, with most phosphorus coming from excipients.

A study of patients receiving hemodialysis in Japan demonstrated the efficacy of tenapanor for treating hyperphosphatemia with fewer daily pills required in a 26-week period.